Holen Sie sich die Stockscreener-App
33.52
4.88%
1.56
Handel nachbörslich:
33.62
0.10
+0.30%
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Inflation Data: Is Stoke Therapeutics Inc. stock a buy in volatile marketsRate Hike & Weekly Consistent Profit Watchlists - Улправда
Aug Swings: What valuation multiples suggest for Stoke Therapeutics Inc stockQuarterly Portfolio Summary & Technical Buy Zone Confirmation - moha.gov.vn
Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK - MarketBeat
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK - MarketBeat
Is Stoke Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Recap & Verified Momentum Stock Watchlist - Улправда
Stoke Therapeutics (FRA:0GT) EV-to-OCF : 25.91 (As of Dec. 19, 2025) - GuruFocus
Analyst Confidence Surges for Stoke Therapeutics Following Key Data - AD HOC NEWS
Equities Analysts Set Expectations for STOK FY2027 Earnings - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Biotech leader Stoke Therapeutics offers multiple entries as revenue surges 117% - MSN
Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright By Investing.com - Investing.com South Africa
Stoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright - Investing.com India
HC Wainwright & Co. Maintains Stoke Therapeutics (STOK) Buy Recommendation - Nasdaq
Stoke Therapeutics Inc diskutieren - sharewise.com
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $50.00 at HC Wainwright - MarketBeat
STOK: HC Wainwright & Co. Raises Price Target to $50 | STOK Stoc - GuruFocus
Stoke Therapeutics Earnings Notes - Trefis
(STOK) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Stoke Therapeutics: A Deep Dive into Clinical Progress and Market Sentiment - AD HOC NEWS
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? - AOL.com
Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock - MarketBeat
Insider Selling Alert: Kaye Edward M. MD Sells Shares of Stoke T - GuruFocus
Stoke Therapeutics Insider Sold Shares Worth $433,385, According to a Recent SEC Filing - marketscreener.com
Dir Kaye Sells 13,430 ($433.4K) Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets
Stoke Therapeutics (NASDAQ:STOK) Shares Up 12.4%Time to Buy? - MarketBeat
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.1%What's Next? - MarketBeat
Marshall Wace LLP Acquires 168,771 Shares of Stoke Therapeutics, Inc. $STOK - MarketBeat
Officer Allan Files To Sell 3,978 Of Stoke Therapeutics Inc [STOK] - TradingView — Track All Markets
With Stoke Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
Stoke Therapeutics highlights Zorevunersen’s potential at epilepsy meeting - MSN
Biogen, Stoke Therapeutics announce data presentations for zorevunersen - MSN
Stoke Therapeutics, Inc. $STOK Shares Purchased by Franklin Resources Inc. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Sells $267,723.36 in Stock - MarketBeat
Jonathan Allan Sells 8,785 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Director Edward Md Kaye Sells 6,453 Shares - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 1,018 Shares of Stock - MarketBeat
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $52,355.52 in Stock - MarketBeat
Allan Jonathan of Stoke Therapeutics sells $306k in shares By Investing.com - Investing.com South Africa
Allan Jonathan of Stoke Therapeutics sells $306k in shares - Investing.com
Stoke Therapeutics Executives Conduct Multiple Stock Sales - TradingView — Track All Markets
Kaye Edward M. MD sells Stoke Therapeutics (STOK) stock for $467k - Investing.com UK
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Fly 36% But Investors Aren't Buying For Growth - 富途牛牛
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome w - GuruFocus
Zorevunersen shows promise for Dravet syndrome in long-term data By Investing.com - Investing.com South Africa
Stoke Therapeutics Highlights Zorevunersen’s Potential at Epilepsy Meeting - TipRanks
Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome - Nasdaq
Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen - marketscreener.com
Stoke Therapeutics, Inc. and Biogen Present Data on Zorevunersen at AES 2025 - TradingView — Track All Markets
Biogen and Stoke Therapeutics Present Promising Long-term Data for Zorevunersen in Treating Dravet Syndrome at AES 2025 - Quiver Quantitative
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - The Manila Times
Biogen (Nasdaq: BIIB) and Stoke share long-term Dravet data on zorevunersen - Stock Titan
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry - simplywall.st
0.67%
1.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):